Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial

Paul Kim, Ana M. Sánchez, Taylor J.R. Penke, Hannah H. Tuson, J. Kime, Robert W. McKee, William L. Slone, Nicholas R. Conley, Lana J. McMillan, Cameron J. Prybol, Paul M. Garofolo